Log in to search using one of your social media accounts:

 

Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes

We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our results demonstrate that achievement of complete response (CR) is imperative at all stages of disease in order to attain long-term disease control. The SMILE regimen was effective in relapsed/refractory disease to achieve complete remission. Autologous stem cell transplant should be strongly considered in patients with advanced ENKL who achieved CR, whereas allo-SCT can be considered for select patients who have not attained a CR.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MOR202 (fully human). CD38 antibodies have pleiotropic mechanisms of action including Fc-dependent immune-effector mechanisms, direct apoptotic activity, and immunomodulatory effects b...
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Lymphoid Neoplasia, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Allogeneic HSCT is a promising treatment modality for CD8+ PCAETL. Because of the aggressive nature of this disease and lack of sustained remission with currently available therapies, HSCT should be considered early in the course of treatment. Two novel agents, brentuximab and pralatrexate, showed significant activity against CD8+ PCAETL, and may be incorporated earlier in the treatment course. Micro-Abstract Several studies have suggested that hematopoietic stem cell transplantation (HSCT) might provide a cure for primary cutaneous aggressive epidermotropic cytotoxic CD8-positive T-cell lymphoma (CD8+ PCAETL). ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We describe the clinicopathologic features of 17 patients who had a hematologic malignancy of various types, were treated, and subsequently developed a lymphoproliferative disorder (LPD). There were 10 men and 7 women with a median age of 59 years (range, 36 to 83 y). The primary hematologic neoplasms included: 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, 3 plasma cell myeloma, 2 acute monoblastic leukemia, and 1 case each of mixed-phenotype acute leukemia, chronic myeloid leukemia, splenic marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, T-cell prolymphocytic leukemia, and peripheral...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
Several studies have suggested that hematopoietic stem cell transplantation (HSCT) might provide a cure for primary cutaneous aggressive epidermotropic cytotoxic CD8-positive T-cell lymphoma (CD8+ PCAETL). We summarize published literature on this disease and present outcomes of 8 patients with CD8+ PCAETL treated at our institution. In our experience, allogeneic HSCT and the novel agents brentuximab and pralatrexate show substantial activity against this disease.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Several studies have suggested that hematopoietic stem cell transplant (HSCT) may provide a cure for Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive T-Cell Lymphoma (CD8+ PCAETL). We summarize published literature on this disease and present outcomes of 8 patients with CD8+ PCAETL treated at our institution. In our experience, allogeneic HSCT and the novel agents brentuximab and pralatrexate demonstrate substantial activity against this disease.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: Available online 12 October 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jonathan E. Brammer, Dai Chihara, L. Michelle Poon, Paolo Caimi, Marcos de Lima, Celina Ledesma, Gabriela Rondon, Stefan O. Ciurea, Yago Nieto, Michele Fanale, Bouthaina Dabaja, Richard T. Maziarz, Richard E. Champlin, Chitra Hosing, Yasuhiro Oki
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year.1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5-15% of all lymphomas.3-5 Patients with advanced stage ENKL (stage III-IV) and relapsed/refractory early stage disease are treated with systemic chemotherapy with or without radiotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders derived from post-thymic T cells and natural killer cells.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Peripheral T-cell lymphomas (PTCL) continue to present a significant clinical challenge both at the time of initial diagnosis and during the relapse. A proportion of patients with PTCL diagnoses can achieve cure or long-term disease control; hence, in the majority of cases, the intent of initial therapy is curative. However, given the advanced age at the time of diagnosis in the majority of PTCL cases, palliative intent frontline therapy should also be explored for a sizable proportion of patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | T-cell Lymphoma | Transplants